Fenben, a broad-spectrum antiparasitic drug used in the veterinary industry to treat parasitic worm infections in animals, has been found to be effective against certain cancers in human cells and animal models. The drug is known for interfering with the ability of cancer cells to use glucose, starving them and causing them to die. The research published in the journal Scientific Reports indicates that fenbendazole may also be effective against tumors that have mutations in the KRAS signaling pathway.
While anthelmintic drugs have been shown to slow the growth of cancer in many laboratory settings, they haven’t been shown to cure cancer in humans, and turning testing results into a clinical treatment is a long process. However, some patients have reported success with self-administering anthelmintic medications.
A recent online case study of a man who used fenben to treat his cancer has gained traction and spread through social media platforms like Twitter and Facebook. The man, named Tippens, says that his tumors shrank after he started taking fenbendazole without a prescription. While his story is encouraging, doctors don’t advise people to try unproven treatments. Moreover, it is important to note that anecdotal evidence may not be valid, since it’s difficult to account for other factors that could have contributed to the tumors’ regression, such as other conventional cancer treatments he underwent.
Researchers at the National Centre for Human Genome Studies and Research (NCHGSR) at Panjab University have reported that fenbendazole, which is already being used to treat parasitic worm infections in various animals, has been found to be effective against some cancers in human cells and animal models. Fenbendazole interferes with microtubules and p53 in cancer cells, which leads to preferential elimination of the tumors both in cell culture and in vivo. The researchers also found that fenbendazole induced autophagy in colorectal cancer cells by activating Beclin-1.
Another study using a mouse model showed that fenbendazole reduced the number of tumors in mice that had KRAS-mutant lung cancer by inhibiting the activity of GTPases, which are important for tumor cell growth and proliferation. This was accompanied by decreased expression of the RAS-related gene pathway.
The researchers found that fenbendazole also induced cell death in cancer cells with KRAS mutations by promoting oxidative stress, inhibiting the expression of key proteins involved in cell cycle control, and inducing apoptosis. They also found that fenbendazole was effective in preventing the development of metastases in a mouse model of metastatic B-cell lymphoma.
Although fenbendazole has been shown to be effective in cancers in laboratory testing, it is not approved for the treatment of human cancers by any regulatory authority. It is not recommended that people take fenbendazole or any other antiparasitic medication to treat their own cancers. Patients should always consult with their doctors before starting a new treatment. They should discuss their options for the best course of action to take, such as participating in clinical trials. This will help ensure that their treatment is as safe and effective as possible. fenben for humans